---
id: native-valve-endocarditis-treatment_078
category: clinical_syndromes
tags: [native-valve-endocarditis, S-aureus, viridans-streptococcus, enterococcus, endocarditis-treatment]
deck: Infectious Diseases
created: 2025-11-10
modified: 2025-11-10
---

## Native Valve Endocarditis: Treatment by Organism

**Q:** What are the organism-specific treatment regimens for native valve endocarditis (viridans streptococcus, S. aureus, enterococcus)?

**A:**

**Treatment Principles:**
- **Prolonged bactericidal therapy** (4-6 weeks)
- **IV antibiotics required** (oral insufficient for cure)
- **Source control:** Consider surgery for complications
- **Monitor for complications:** Heart failure, abscess, emboli

---

## 1. VIRIDANS STREPTOCOCCUS & *STREPTOCOCCUS GALLOLYTICUS* (S. bovis)

**Organisms:**
- **Viridans streptococci:** *S. mitis*, *S. sanguinis*, *S. mutans*, *S. salivarius*, *S. anginosus group*
- ***Streptococcus gallolyticus* (formerly *S. bovis*):** Associated with **colon cancer** (screen with colonoscopy)

---

### **A. Penicillin-Susceptible (MIC ≤0.12 μg/mL) - MOST COMMON**

**Standard Regimen (4 Weeks):**

| **Agent** | **Dosing** | **Duration** |
|-----------|------------|--------------|
| **Penicillin G** | 12-18 million units/day IV continuous infusion OR divided q4h | 4 weeks |
| **Ceftriaxone** (alternative) | 2g IV/IM q24h | 4 weeks |
| **Vancomycin** (PCN allergy) | 15 mg/kg IV q12h | 4 weeks |

**Efficacy:** **Cure rate >95%**

---

**Short-Course Regimen (2 Weeks) - Select Patients:**

**Combination:**
- **Penicillin G** 12-18 million units/day IV continuous OR divided q4h
  **PLUS**
- **Gentamicin** 3 mg/kg IV/IM q24h

**OR**

- **Ceftriaxone** 2g IV/IM q24h
  **PLUS**
- **Gentamicin** 3 mg/kg IV/IM q24h

**Duration:** **2 weeks**

**Eligibility Criteria for 2-Week Regimen:**
- **Native valve** (NOT prosthetic)
- **No complications:** No heart failure, abscess, emboli, conduction abnormalities
- **No vegetation >10-15 mm**
- **Rapid clinical response** (<7 days to defervescence)
- **Penicillin-susceptible** (MIC ≤0.12 μg/mL)

**Efficacy:** **Non-inferior to 4-week monotherapy** (for eligible patients)

**Key Point:** **2-week regimen = convenient** (shorter duration, once-daily dosing)

---

### **B. Penicillin-Intermediate (MIC 0.12-0.5 μg/mL)**

**Regimen:**

| **Agent** | **Dosing** | **Duration** |
|-----------|------------|--------------|
| **Penicillin G** | 24 million units/day IV continuous infusion OR divided q4h | 4 weeks |

**Efficacy:** Higher dose penicillin required

---

### **C. Penicillin-Resistant (MIC >0.5 μg/mL) - RARE**

**Treat as Enterococcus** (see below)

**Regimen:**
- **Penicillin G** 24 million units/day IV + **Gentamicin** 3 mg/kg IV q24h x 4-6 weeks
- OR **Vancomycin** 15 mg/kg IV q12h x 6 weeks

---

## 2. STAPHYLOCOCCUS AUREUS

**Most Common Cause of Acute Endocarditis:**
- **Native valve:** S. aureus = #1 cause (especially IVDU, healthcare-associated)
- **High mortality:** 20-40% (even with treatment)

---

### **A. Methicillin-Susceptible *S. aureus* (MSSA)**

**First-Line Regimen:**

| **Agent** | **Dosing** | **Duration** |
|-----------|------------|--------------|
| **Nafcillin** OR **Oxacillin** | 2g IV q4h (12g/day) | 6 weeks |

**Alternative (β-Lactam Allergy):**
- **Cefazolin** 2g IV q8h x 6 weeks (if non-severe allergy)
- **Vancomycin** 15 mg/kg IV q8-12h x 6 weeks (if severe allergy)

**Key Point:** **Nafcillin/oxacillin preferred over vancomycin** for MSSA (better outcomes)

---

**Adjunctive Gentamicin? (Controversial)**

**Not Recommended:**
- **No survival benefit** in meta-analyses
- **↑ Nephrotoxicity**
- **IDSA 2015:** Does NOT recommend routine gentamicin for MSSA

---

### **B. Methicillin-Resistant *S. aureus* (MRSA)**

**First-Line Regimen:**

| **Agent** | **Dosing** | **Duration** |
|-----------|------------|--------------|
| **Vancomycin** | 15-20 mg/kg IV q8-12h (target trough 15-20 μg/mL) | 6 weeks |

**Alternative (Vancomycin Intolerance or Failure):**
- **Daptomycin** 8-10 mg/kg IV q24h x 6 weeks (higher dose for endocarditis)

**Key Point:** **Daptomycin NOT for pneumonia** (inactivated by surfactant), but OK for endocarditis

---

**Adjunctive Rifampin? (NOT Recommended)**

**IDSA 2015:**
- **Do NOT add rifampin** routinely
- No benefit in RCTs
- ↑ Drug interactions, hepatotoxicity

---

**Duration:**
- **Uncomplicated right-sided (tricuspid) IE:** **2 weeks** (if IVDU, rapid response, no metastatic foci)
- **Left-sided IE:** **6 weeks** (minimum 4 weeks)

---

## 3. ENTEROCOCCUS

**Organisms:**
- ***Enterococcus faecalis* (80-90%):** Usually ampicillin-susceptible
- ***Enterococcus faecium* (10-20%):** Often ampicillin-resistant (VRE)

**Key Point:** **Enterococcus requires COMBINATION therapy** (β-lactam or vancomycin + gentamicin)

---

### **A. Ampicillin-Susceptible *E. faecalis***

**First-Line Regimen (Gentamicin-Susceptible):**

| **Agent** | **Dosing** | **Duration** |
|-----------|------------|--------------|
| **Ampicillin** | 2g IV q4h (12g/day) | 4-6 weeks |
| **PLUS** | | |
| **Gentamicin** | 3 mg/kg IV q24h | 2 weeks |

**OR**

| **Agent** | **Dosing** | **Duration** |
|-----------|------------|--------------|
| **Penicillin G** | 24 million units/day IV continuous OR divided q4h | 4-6 weeks |
| **PLUS** | | |
| **Gentamicin** | 3 mg/kg IV q24h | 2 weeks |

**Key Point:** **Gentamicin x 2 weeks only** (then continue ampicillin alone for total 4-6 weeks)

---

**Alternative (PCN Allergy):**

| **Agent** | **Dosing** | **Duration** |
|-----------|------------|--------------|
| **Vancomycin** | 15 mg/kg IV q12h | 6 weeks |
| **PLUS** | | |
| **Gentamicin** | 3 mg/kg IV q24h | 6 weeks |

---

### **B. High-Level Aminoglycoside Resistance (HLAR)**

**Definition:** Gentamicin MIC >500 μg/mL (synergy lost)

**Regimen:**

| **Agent** | **Dosing** | **Duration** |
|-----------|------------|--------------|
| **Ampicillin** | 2g IV q4h | 8-12 weeks |
| **PLUS** | | |
| **Ceftriaxone** | 2g IV q12h | 8-12 weeks |

**Key Point:** **Double β-lactam regimen** (ampicillin + ceftriaxone) for HLAR enterococcus

---

### **C. Ampicillin-Resistant *E. faecium* (VRE)**

**Vancomycin-Susceptible *E. faecium*:**

| **Agent** | **Dosing** | **Duration** |
|-----------|------------|--------------|
| **Vancomycin** | 15 mg/kg IV q12h | 6 weeks |
| **PLUS** | | |
| **Gentamicin** | 3 mg/kg IV q24h | 6 weeks |

---

**Vancomycin-Resistant *E. faecium* (VRE):**

**Options:**
- **Daptomycin** 10-12 mg/kg IV q24h (consider adding ampicillin or gentamicin for synergy)
- **Linezolid** 600 mg IV/PO q12h (⚠️ NOT bactericidal, ↑ relapse risk)

**Key Point:** **VRE endocarditis = difficult to treat** (poor outcomes, high relapse)

---

## 4. HACEK ORGANISMS

**Organisms:**
- *Haemophilus* species (*H. parainfluenzae*, *H. aphrophilus*)
- *Aggregatibacter* (*A. actinomycetemcomitans*, *A. aphrophilus*)
- *Cardiobacterium hominis*
- *Eikenella corrodens*
- *Kingella kingae*

**Characteristics:**
- **Slow-growing Gram-negative bacilli**
- **Oral/oropharyngeal flora**
- Previously required extended incubation (now detected in 5-7 days with modern blood culture systems)

---

**Treatment:**

| **Agent** | **Dosing** | **Duration** |
|-----------|------------|--------------|
| **Ceftriaxone** (preferred) | 2g IV/IM q24h | 4 weeks (NVE)<br>6 weeks (PVE) |

**Alternative:**
- **Ampicillin-sulbactam** 3g IV q6h (if β-lactamase negative)
- **Fluoroquinolone** (ciprofloxacin, levofloxacin) - if β-lactam allergy

**Key Point:** **Ceftriaxone = first-line** (once-daily dosing)

---

## 5. CULTURE-NEGATIVE ENDOCARDITIS

**Causes:**
- **Prior antibiotics** (#1 cause)
- **Fastidious organisms:** *Coxiella burnetii* (Q fever), *Bartonella*, *Tropheryma whipplei* (Whipple), *Mycoplasma hominis*
- **Fungi:** *Candida*, *Aspergillus* (rare)
- **Non-infectious:** Marantic endocarditis (cancer), Libman-Sacks (SLE)

---

**Empiric Regimen (Community-Acquired, Native Valve):**

| **Agent** | **Dosing** | **Duration** |
|-----------|------------|--------------|
| **Ampicillin-sulbactam** | 3g IV q6h | 4-6 weeks |
| **PLUS** | | |
| **Gentamicin** | 3 mg/kg IV q24h | 2 weeks |

**Covers:** Viridans strep, HACEK, *Bartonella*

---

**Empiric Regimen (Healthcare-Associated, Prosthetic Valve, or IVDU):**

| **Agent** | **Dosing** | **Duration** |
|-----------|------------|--------------|
| **Vancomycin** | 15 mg/kg IV q12h | 6 weeks |
| **PLUS** | | |
| **Gentamicin** | 3 mg/kg IV q24h | 2 weeks |
| **PLUS** | | |
| **Cefepime** OR **Ceftazidime** | 2g IV q8h | 6 weeks |

**Covers:** MRSA, Gram-negatives (including *Pseudomonas*)

---

**Specific Organisms:**

***Coxiella burnetii* (Q Fever Endocarditis):**
- **Doxycycline** 100 mg PO BID + **Hydroxychloroquine** 200 mg PO TID x **≥18 months**
- Monitor IgG phase I titer (goal <1:200)

***Bartonella* (Cat-Scratch Disease):**
- **Doxycycline** 100 mg IV/PO BID x 6 weeks + **Gentamicin** 3 mg/kg IV q24h x 2 weeks

---

## SURGICAL INDICATIONS

**IDSA 2015 Class I Indications (Early Surgery During Antibiotic Therapy):**

**1. Heart Failure (Most Common Indication):**
- **Acute aortic or mitral regurgitation** with heart failure
- **Severe valvular dysfunction** (stenosis or regurgitation)

**2. Uncontrolled Infection:**
- **Perivalvular abscess**, fistula, or enlarging vegetation
- **Persistent bacteremia** despite appropriate antibiotics (>5-7 days)
- **Fungal endocarditis** (almost always requires surgery)

**3. Prevention of Embolism:**
- **Vegetation >10 mm** (especially anterior mitral leaflet) + embolic event
- **Recurrent emboli** despite antibiotics

---

**Timing:**
- **Urgent surgery (<24-48h):** Severe heart failure, abscess with conduction block
- **Early surgery (within days-weeks):** Large vegetation (>10 mm), recurrent emboli

---

## MONITORING & FOLLOW-UP

**During Treatment:**
- **Repeat blood cultures** every 2-3 days until clearance documented
- **Monitor for complications:**
  - Heart failure (daily exam, echo)
  - Emboli (neurologic exam, imaging)
  - Abscess (ECG for conduction abnormalities, echo)
- **Renal function** (if gentamicin or vancomycin)

**Post-Treatment:**
- **Repeat TTE** at end of therapy (baseline for future)
- **Dental evaluation** (if viridans strep)
- **Colonoscopy** (if *S. gallolyticus* - associated with colon cancer)
- **Follow-up echo** at 1-3 months (assess valve function)

---

## DURATION OF THERAPY

| **Organism** | **Native Valve** | **Prosthetic Valve** |
|--------------|------------------|----------------------|
| **Viridans strep (PCN-susceptible)** | 4 weeks (2 weeks if eligible) | 6 weeks |
| **S. aureus (left-sided)** | 6 weeks | 6-8 weeks |
| **S. aureus (right-sided, uncomplicated)** | 2 weeks | N/A |
| **Enterococcus** | 4-6 weeks | 6 weeks |
| **HACEK** | 4 weeks | 6 weeks |
| **Culture-negative** | 4-6 weeks | 6 weeks |

---

**Mnemonic: "SAVED" (Surgical Indications)**
- **S**evere heart failure (valvular dysfunction)
- **A**bscess (perivalvular)
- **V**egetation >10 mm + embolism
- **E**mboli (recurrent)
- **D**espite antibiotics (persistent bacteremia >5-7 days)

**Mnemonic: "SOS for S. aureus"**
- **S**ix weeks (left-sided)
- **O**xacillin/nafcillin (MSSA preferred)
- **S**urgery often needed (40-50%)

**Mnemonic: "EASE for Enterococcus"**
- **E**nterococcus = combination therapy (β-lactam + gentamicin)
- **A**mpicillin + gentamicin (first-line)
- **S**ynergy required (gentamicin x 2 weeks minimum)
- **E**ight-twelve weeks if HLAR (double β-lactam: ampicillin + ceftriaxone)

**Clinical Pearls:**
- **Viridans strep:** 2-week regimen (penicillin + gentamicin) = non-inferior to 4-week (for eligible patients)
- **S. aureus:** Nafcillin/oxacillin preferred over vancomycin for MSSA (better outcomes)
- **S. aureus right-sided IE (IVDU):** 2 weeks sufficient if uncomplicated
- **Enterococcus:** ALWAYS combination therapy (β-lactam or vancomycin + gentamicin x 2 weeks minimum)
- **HLAR enterococcus:** Ampicillin + ceftriaxone (double β-lactam) x 8-12 weeks
- **HACEK:** Ceftriaxone 2g q24h x 4 weeks (once-daily dosing convenient)
- **Q fever endocarditis:** Doxycycline + hydroxychloroquine x ≥18 months (monitor IgG titer)
- **Gentamicin for endocarditis:** Once-daily dosing (3 mg/kg q24h)
- **Surgery indications:** Heart failure (most common), abscess, persistent bacteremia, large vegetation (>10 mm) + embolism
- **S. gallolyticus (S. bovis) endocarditis:** Screen for colon cancer (colonoscopy)
- **Daptomycin dose for endocarditis:** 8-10 mg/kg q24h (higher than for bacteremia)
- **VRE endocarditis = difficult** (linezolid NOT bactericidal, daptomycin preferred)

**Media:** None

**Sources:** [IDSA 2015 - Infective Endocarditis Guidelines], [AHA 2021 - Infective Endocarditis Scientific Statement], [ESC/EACTS 2023 - Endocarditis Guidelines], [PMC 2024 - Short-course therapy viridans strep endocarditis], [JAMA 2023 - S. aureus endocarditis management]
